Related Experiment Video

Updated: Aug 2, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K

The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis

Gang Fan1, Dian-Long Guo1

  • 1Cardiology Department of Xianyang First People's Hospital, Xianyang, ShaanXi 712000, PR China.

European Journal of Internal Medicine
|April 16, 2023
PubMed
Abstract

Insights

Sodium-glucose co-transporter 2 inhibitors (SGLT2is) significantly reverse cardiac remodeling and improve cardiac function in heart failure patients. Empagliflozin demonstrates particularly potent anti-remodeling effects, suggesting its promise in clinical practice.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Sodium-glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure prognosis, irrespective of diabetes status.
  • The impact of SGLT2is on cardiac structural remodeling and function remains incompletely understood.

Approach:

  • A meta-analysis of published randomized controlled trials (RCTs) was conducted.
  • Compared SGLT2is treatment against control therapy in patients with or without heart failure.
  • Utilized Review Manager 5.3 software for meta-analysis.

Key Points:

  • Analyzed 15 RCTs involving 1343 patients; 663 received SGLT2is, 680 received control therapy.
  • SGLT2is significantly improved heart rate, left atrium volume index, E/e', left ventricular mass index, left ventricular end-systolic volume, and left ventricular ejection fraction.
  • Empagliflozin showed superior reductions in LVEDV, LVESV, LVMi, LAVi, E/e', and greater LVEF increase compared to other SGLT2is.
  • Cardiac anti-remodeling effects were most pronounced in heart failure patients.

Conclusions:

  • SGLT2is, especially empagliflozin, effectively reverse cardiac remodeling in heart failure patients.
  • Empagliflozin shows potential as a clinical agent for reversing cardiac remodeling.
  • These findings support the role of SGLT2is in managing cardiac structural changes in heart failure.
Keywords:
Cardiac remodelingEmpagliflozinHeart failureMeta-analysisSGLT2i

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

232

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.8K
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
645